USD 2.52
(2.02%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 29.75 Million USD | 5.92% |
2022 | 28.29 Million USD | -21.06% |
2021 | 35.84 Million USD | 8.99% |
2020 | 32.88 Million USD | 1.98% |
2019 | 32.24 Million USD | -30.56% |
2018 | 46.44 Million USD | -1.39% |
2017 | 47.09 Million USD | 33.02% |
2016 | 35.4 Million USD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 15.57 Million USD | 103.2% |
2024 Q1 | 7.66 Million USD | -10.12% |
2024 Q3 | 13.54 Million USD | -41.53% |
2023 Q2 | 6.62 Million USD | 3.55% |
2023 Q1 | 6.39 Million USD | 18.97% |
2023 FY | 29.96 Million USD | 5.92% |
2023 Q4 | 8.52 Million USD | 3.94% |
2023 Q3 | 8.2 Million USD | 23.85% |
2022 FY | 28.29 Million USD | -21.06% |
2022 Q1 | 8.05 Million USD | 4.46% |
2022 Q4 | 5.37 Million USD | -21.37% |
2022 Q3 | 6.83 Million USD | -14.77% |
2022 Q2 | 8.02 Million USD | -0.41% |
2021 FY | 35.84 Million USD | 8.99% |
2021 Q1 | 8.36 Million USD | 91.81% |
2021 Q2 | 10.87 Million USD | 30.05% |
2021 Q3 | 8.88 Million USD | -18.31% |
2021 Q4 | 7.71 Million USD | -13.22% |
2020 Q4 | 4.36 Million USD | -17.44% |
2020 Q2 | 18.13 Million USD | 255.19% |
2020 FY | 32.88 Million USD | 1.98% |
2020 Q1 | 5.1 Million USD | -46.96% |
2020 Q3 | 5.28 Million USD | -70.88% |
2019 Q2 | 5.7 Million USD | -37.52% |
2019 FY | 32.24 Million USD | -30.56% |
2019 Q4 | 9.62 Million USD | 23.82% |
2019 Q3 | 7.77 Million USD | 36.19% |
2019 Q1 | 9.13 Million USD | -24.09% |
2018 Q2 | 8.95 Million USD | -49.62% |
2018 FY | 46.44 Million USD | -1.39% |
2018 Q4 | 12.03 Million USD | 56.83% |
2018 Q3 | 7.67 Million USD | -14.29% |
2018 Q1 | 17.77 Million USD | 170.14% |
2017 Q2 | 6 Million USD | -51.02% |
2017 Q3 | 22.26 Million USD | 271.04% |
2017 Q1 | 12.25 Million USD | 0.0% |
2017 Q4 | 6.58 Million USD | -70.45% |
2017 FY | 47.09 Million USD | 33.02% |
2016 FY | 35.4 Million USD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Collegium Pharmaceutical, Inc. | 326.16 Million USD | 90.878% |
Embecta Corp. | 749.9 Million USD | 96.033% |
ANI Pharmaceuticals, Inc. | 305.3 Million USD | 90.255% |
Dynavax Technologies Corporation | 182.11 Million USD | 83.663% |
Esperion Therapeutics, Inc. | 73.06 Million USD | 59.281% |
Pacira BioSciences, Inc. | 490.3 Million USD | 93.932% |
PainReform Ltd. | -15 Thousand USD | 198446.667% |
Sunshine Biopharma, Inc. | 8.33 Million USD | -256.774% |
SCYNEXIS, Inc. | 124.51 Million USD | 76.106% |
China SXT Pharmaceuticals, Inc. | 553.97 Thousand USD | -5270.678% |
Cosmos Health Inc. | 4.34 Million USD | -584.022% |
Journey Medical Corporation | 52.52 Million USD | 43.352% |
Sunshine Biopharma, Inc. | 8.33 Million USD | -256.774% |
Safety Shot Inc | -74.45 Thousand USD | 40058.634% |
Alpha Teknova, Inc. | 10.29 Million USD | -188.967% |
Intra-Cellular Therapies, Inc. | 430.62 Million USD | 93.091% |
Bright Green Corporation | -237.01 Thousand USD | 12652.739% |
Procaps Group, S.A. | 239.56 Million USD | 87.581% |
Theratechnologies Inc. | 62.12 Million USD | 52.113% |
Harrow Health, Inc. | 90.55 Million USD | 67.144% |
Sonoma Pharmaceuticals, Inc. | 4.74 Million USD | -527.018% |
Biofrontera Inc. | 16.62 Million USD | -78.938% |
DURECT Corporation | 6.83 Million USD | -335.544% |
Supernus Pharmaceuticals, Inc. | 523.74 Million USD | 94.319% |
Cronos Group Inc. | 6.99 Million USD | -325.582% |
OptiNose, Inc. | 62.35 Million USD | 52.285% |
Ironwood Pharmaceuticals, Inc. | 441.16 Million USD | 93.256% |
Kala Pharmaceuticals, Inc. | -303 Thousand USD | 9919.142% |
RedHill Biopharma Ltd. | 3.05 Million USD | -874.143% |
Organogenesis Holdings Inc. | 309.79 Million USD | 90.396% |
Guardion Health Sciences, Inc. | 5.39 Million USD | -451.523% |
Cumberland Pharmaceuticals Inc. | 33.48 Million USD | 11.151% |
Radius Health, Inc. | 307.71 Million USD | 90.331% |
Universe Pharmaceuticals INC | 10.07 Million USD | -195.221% |
ProPhase Labs, Inc. | 16.23 Million USD | -83.213% |
Phibro Animal Health Corporation | 312.48 Million USD | 90.479% |
Procaps Group S.A. | 239.56 Million USD | 87.581% |
Alvotech | -69.42 Million USD | 142.857% |
TherapeuticsMD, Inc. | 1.3 Million USD | -2185.1% |
Viatris Inc. | 6.43 Billion USD | 99.538% |
Rockwell Medical, Inc. | 8.7 Million USD | -241.82% |
Aytu BioPharma, Inc. | 54.58 Million USD | 45.495% |
SIGA Technologies, Inc. | 122.09 Million USD | 75.632% |
Tilray Brands, Inc. | 223.35 Million USD | 86.679% |
Lifecore Biomedical, Inc. | 41.85 Million USD | 28.908% |
Shineco, Inc. | 882.16 Thousand USD | -3272.6% |
PetIQ, Inc. | 252.74 Million USD | 88.228% |
Regencell Bioscience Holdings Limited | -745.58 Thousand USD | 4090.408% |
Incannex Healthcare Limited | 12 Thousand USD | -247833.333% |
Neurocrine Biosciences, Inc. | 1.84 Billion USD | 98.39% |
Alimera Sciences, Inc. | 61.17 Million USD | 51.362% |
Silver Spike Investment Corp. | 8.1 Million USD | -267.191% |
Assertio Holdings, Inc. | 125.04 Million USD | 76.208% |
Shuttle Pharmaceuticals Holdings, Inc. | -6811.00 USD | 436922.787% |
Petros Pharmaceuticals, Inc. | 4.19 Million USD | -609.874% |
Clever Leaves Holdings Inc. | 6.55 Million USD | -353.813% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 1334.433% |
Avadel Pharmaceuticals plc | 27.11 Million USD | -9.717% |
Hempacco Co., Inc. | -1.21 Million USD | 2547.047% |
Talphera, Inc. | -4.89 Million USD | 707.804% |
Alvotech | -69.42 Million USD | 142.857% |
Eagle Pharmaceuticals, Inc. | 221.67 Million USD | 86.578% |
Lantheus Holdings, Inc. | 709.54 Million USD | 95.807% |
Currenc Group, Inc. | 17.35 Million USD | -71.419% |
Kamada Ltd. | 52.59 Million USD | 43.429% |
Indivior PLC | 907 Million USD | 96.72% |
Evoke Pharma, Inc. | 4.97 Million USD | -497.58% |
Flora Growth Corp. | 17.73 Million USD | -67.73% |
Cyclo Therapeutics, Inc. | -2.41 Million USD | 1334.433% |
Evolus, Inc. | 140.52 Million USD | 78.828% |
HUTCHMED (China) Limited | 453.55 Million USD | 93.44% |
Amphastar Pharmaceuticals, Inc. | 343.96 Million USD | 91.35% |
Akanda Corp. | 111.44 Thousand USD | -26595.619% |